Managers / Q3 2022 · view latest →
LORD, ABBETT & CO. LLC
CIK 0000728100 · 30 HUDSON STREET, JERSEY CITY, NJ, 07302 · 201-827-2000
Summary
Lord, Abbett & Co. LLC reported $27.4B in U.S.-listed holdings across 865 positions for Q3 2022.
Its largest position, MSFT, represents 3.3% of the portfolio.
Compared with Q2 2022, the fund opened 97 new positions and exited 96.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 83.3% · $22.8B
- US DOMESTIC · 5.7% · $1.5B
- Other · 4.0% · $1.1B
- REIT · 2.2% · $609M
- PUBLIC · 2.1% · $573M
- Other · 2.7% · $753M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| MLB1MERCADOLIBRE INC COM | NEW | +148.5K | 148.5K | +$123M | $123M |
| ALNYALNYLAM PHARMACEUTICALS INC COM | NEW | +519.1K | 519.1K | +$104M | $104M |
| SBUXSTARBUCKS CORP COM | NEW | +1.21M | 1.21M | +$102M | $102M |
| SCHWSCHWAB CHARLES CORP COM | NEW | +1.22M | 1.22M | +$88M | $88M |
| SNOWSNOWFLAKE INC CL A | NEW | +490.2K | 490.2K | +$83M | $83M |
| APLSUSDAPELLIS PHARMACEUTICALS INC COM | NEW | +946.5K | 946.5K | +$65M | $65M |
| GKOSGLAUKOS CORP COM | NEW | +1.15M | 1.15M | +$61M | $61M |
| VTYXUSDVENTYX BIOSCIENCES INC COM | NEW | +1.74M | 1.74M | +$61M | $61M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2022
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $31M | 557 | May 14, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $33M | 623 | Feb 13, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $34M | 609 | Nov 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $31M | 593 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $28M | 625 | May 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $32M | 598 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $31M | 775 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $30M | 760 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $30M | 794 | May 9, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $28M | 749 | Feb 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $27M | 779 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $29M | 830 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $28M | 825 | May 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | Under review | 882 | Feb 10, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $27.4B | 865 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $28.3B | 832 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $37.5B | 894 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $43.9B | 876 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $41.8B | 918 | Nov 9, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $41.5B | 884 | Aug 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $39.2B | 735 | May 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $37.9B | 796 | Feb 9, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $31.3B | 766 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $28.6B | 717 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $22.6B | 777 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $30.0B | 810 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $29.4B | 798 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $30.8B | 832 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $30.0B | 779 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $27.4B | 839 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.